Business Standard

Covaxin's phase 1 trial data shows robust response: Bharat Biotech

Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

The company is in the middle of conducting a phase 3 trial with 22,000 subjects

Sohini Das Mumbai
Indigenous vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech International (BBIL), appeared to inch closer to an approval as its phase 1 clinical trial results showed a ‘’robust’’ immune  response without any serious adverse events, the firm said in a research paper.

Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies. The company is in the middle of conducting a phase 3 trial with 22,000 subjects. Serum Institute of India, which is partnering Astra Zeneca and Oxford University for Covid vaccine, has also sought an emergency approval. Pfizer-BioNTech too has applied

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 16 2020 | 10:48 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com